Baxter International, Inc.

778 articles with Baxter International, Inc.

• Baxter Announces U.S. FDA Approval of Myxredlin, The First and Only Ready-To-Use Insulin for IV Infusion

  7/22/2019

  Offers extended shelf life of 30 days at room temperature or 24 months refrigerated

• 

  Baxter International Nabs FDA Approval for Insulin IV Infusion

  7/22/2019

  Myxredlin is intended for use only in acute care settings under medical supervision.

• Baxter Declares Quarterly Dividend Payable October 1, 2019

  7/16/2019

  The dividend is payable on October 1, 2019, to shareholders of record as of August 30, 2019.

• Baxter Supports Advancing American Kidney Health Initiative and Plans Significant U.S. Investment to Help Drive Implementation

  7/10/2019

  Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced its full support of the Administration’s Advancing American Kidney Health Initiative introduced today.

• Baxter Highlights Progress Toward Its 2020 Corporate Responsibility Goals and Efforts to Make a Meaningful Difference Around the World

  6/27/2019

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today the release of its 2018 Corporate Responsibility Report, which showcases the company’s progress on key initiatives to drive more sustainable operations, enhance product quality, build healthy communities, foster a strong work environment and improve access to healthcare.

• Baxter Highlights Renal Care Data about Patients’ Health-Related, Quality of Life Outcomes at the 56th ERA-EDTA Congress

  6/17/2019

  In total, 19 abstracts were presented on Baxter’s therapy options

• Baxter Leads Hemodialysis Research Consortium for German Federal Ministry of Education and Research

  6/14/2019

  Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced receipt of a major research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF)’s “From Material to Innovation” program to lead a consortium investigating an anticoagulation-free hemodialysis (HD) option for end-stage renal disease (ESRD) patients

• Baxter Launches Sharesource 2.0 Telehealth Platform to Support Greater Clinical Insights and Personalized Peritoneal Dialysis Care

  6/11/2019

  Enhancements designed to give healthcare providers access to more comprehensive treatment data and improve clinic workflow

• Baxter to Host Second Quarter 2019 Financial Results Conference Call for Investors

  6/11/2019

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second quarter 2019 financial results on Thursday, July 25, 2019, at 7:30 a.m. Central Time.

• The Baxter International Foundation Commits $2 Million+ to Operation Smile Care Centers in India

  6/4/2019

  Grant increases the availability of safe surgical care for cleft conditions

• Baxter Announces New Research on 3-in-1 Oxiris Set for CRRT and Sepsis Management

  5/28/2019

  Baxter International Inc. announced that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury patients with sepsis.

• Baxter to Conduct Fixed Income Investor Presentations

  5/9/2019

  Baxter International Inc. announced that representatives of the company will conduct a series of Fixed Income Investor Presentations on Thursday, May 9, 2019.

• Baxter Named a “Best Company for Multicultural Women” by Working Mother

  5/7/2019

  Baxter International Inc., a leading global medical products company, announced that it has been named a 2019 Best Company for Multicultural Women by Working Mother magazine.

• Baxter Increases Dividend and Declares Quarterly Dividend

  5/7/2019

  The indicated annual dividend rate is now $0.88 per share of common stock.

• Baxter, NAACP and the Alliance for Home Dialysis Expand Program to Increase Awareness of Kidney Care among African Americans

  4/26/2019

  Baxter International Inc. (NYSE:BAX), a global leader in renal care, along with the National Association for the Advancement of Colored People (NAACP) and the Alliance for Home Dialysis, today announced that the Dialysis Health Imperative for Access, Choice, and Equity (ACE) program will be expanded for a third year.

• Baxter Reports First-Quarter 2019 Results

  4/25/2019

  First-quarter revenue of $2.6 billion declined 2 percent on a reported basis and increased 2 percent on an operational basis

• Baxter to Present at the Bank of America Merrill Lynch Health Care Conference 2019

  4/16/2019

  Baxter International Inc., a leading global medical products company, will present at the 2019 Bank of America Merrill Lynch Health Care Conference in Las Vegas on May 15, 2019.

• Baxter Unveils the Latest Evolution of Floseal at AORN Meeting

  4/9/2019

  Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced that it has received U.S. Food and Drug Administration (FDA) approval for faster preparation of its leading hemostatic product, Floseal Hemostatic Matrix, at the 2019 Association of periOperative Registered Nurses (AORN) Global Surgical Conference and Expo.

• Baxter to Host Webcast of Annual Meeting of Stockholders

  4/4/2019

  Baxter International Inc., a leading global medical products company, will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 7, 2019 at 9 a.m. Central Daylight Time.

• Baxter Highlights Advancements in Clinical Nutrition at ASPEN Conference

  3/26/2019

  Reinforces the company’s efforts to innovate nutrition formulations and delivery mechanisms to meet the needs of patients